Sumatriptan/Naratriptan/Treximet Pregnancy Registry
Please note that the Sumatriptan/Naratriptan/Treximet pregnancy registry stopped new enrollment on January 31, 2012, but will continue to follow-up enrolled women. Healthcare providers can obtain registry results by calling the registry project office directly at 1-800-336-2176 (toll-free) or (910) 256-0549 OR by completing the follow-up form that is linked below and either return the form to the registry by fax at (800) 800-1052 or (910) 256-0637 or by mail to:
Sumatriptan, Naratriptan and Treximet Pregnancy Registry
Information collected at the time of registration included timing, dose and duration of the drug exposure, estimated date of delivery, and sufficient contact information to allow for follow-up of the subsequent pregnancy outcome.
Measures are in place to protect patient confidentiality. The registry advocates the use of an identifier (not patient names) assigned by the registry for the purpose of obtaining follow-up information. Around the patient's estimated date of delivery a short follow-up form was sent to the registering healthcare provider to report on the pregnancy course and outcome. An interim report for each registry is prepared semi-annually following an independent review of data by a scientific advisory committee with expertise in obstetrics, teratology, epidemiology, pediatrics, internal medicine, clinical genetics, and the relevant therapeutic areas. This report is made available to interested healthcare providers upon request by calling the registry.